Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell - Taheri, Fatemeh Hajari; Hassani, Mahmoud; Sharifzadeh, Zahra; Behdani, Mahdi; Abdoli, Shahryar; Sayadi, Mahtab; Bagherzadeh, Kowsar; Arashkia, Arash; Abolhassani, Mohsen (BMC biotechnology, 2024)
Keywords: Antibodies; Antigens; Cancer; Cancer immunotherapy; Care and treatment; CD25 antigen; CD28 antigen; CD69 antigen; Cells; Chimeric antigen receptor (CAR); Chimeric antigen receptors; Complications and side effects; Cytokines; Cytolytic activity; Cytotoxicity; domain; Health aspects; Hinge; IgG1 CH2-CH3; Immunoglobulin G; Immunotherapy; interleukin-2; Intracellular; Intracellular signalling; Ligands; Lymphocytes; Lymphocytes T; Nanobodies; neoplasms; Patient outcomes; secretion; Solid tumors; Spacer domain; T cells; T-lymphocytes; Tumor necrosis factor; Vascular endothelial growth factor; vascular endothelial growth factor receptor-2; VEGFR2; γ-Interferon; Iran; VEGFR2; Chimeric antigen receptor (CAR); Spacer domain; Hinge; IgG1 CH2-CH3